Single Arm Feasibility of Multi-maintenance Olaparib After Disease Recurrence in Participants With Platinum Sensitive BRCAm High Grade Serous Ovarian Cancer
Latest Information Update: 21 Feb 2023
At a glance
- Drugs Cediranib (Primary) ; Olaparib (Primary)
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Acronyms MOLTO
- 17 Feb 2023 Results published in the Clinical Cancer Research
- 04 Feb 2022 Status changed from active, no longer recruiting to completed.
- 25 Sep 2019 Planned End Date changed from 1 Dec 2020 to 29 Sep 2022.